BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 29624648)

  • 21. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case of neurodegenerative Langerhans cell histiocytosis exhibiting high osteopontin in cerebrospinal fluid without specific radiological abnormalities.
    Sakai Y; Ikawa Y; Takenaka M; Noguchi K; Fukuda M; Fujiki T; Kuroda R; Mase S; Araki R; Maeba H; Nishimura R; Wada T
    Int J Hematol; 2023 Nov; 118(5):661-665. PubMed ID: 37523079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis.
    Lonardi S; Scutera S; Licini S; Lorenzi L; Cesinaro AM; Gatta LB; Castagnoli C; Bollero D; Sparti R; Tomaselli M; Medicina D; Calzetti F; Cassatella MA; Facchetti F; Musso T; Vermi W
    Cancer Immunol Res; 2020 Jun; 8(6):829-841. PubMed ID: 32238382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.
    Schwentner R; Kolenová A; Jug G; Schnöller T; Ahlmann M; Meister B; Lehrnbecher T; Minkov M; Hutter C
    Pediatr Res; 2019 May; 85(6):856-864. PubMed ID: 30474648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside.
    Allen CE; Flores R; Rauch R; Dauser R; Murray JC; Puccetti D; Hsu DA; Sondel P; Hetherington M; Goldman S; McClain KL
    Pediatr Blood Cancer; 2010 Mar; 54(3):416-23. PubMed ID: 19908293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous adult xanthogranuloma with a small portion of BRAF
    Ishikawa M; Endo Y; Uehara A; Suto M; Yasuda M; Motegi SI; Ishikawa O
    J Dermatol; 2019 Feb; 46(2):161-165. PubMed ID: 30536719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Langerhans cell histiocytosis.
    Rodriguez-Galindo C; Allen CE
    Blood; 2020 Apr; 135(16):1319-1331. PubMed ID: 32106306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
    Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
    Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for the Prevention of Central Nervous System Complications in Patients with Langerhans Cell Histiocytosis: The Problem of Neurodegenerative Syndrome.
    Imashuku S; Arceci RJ
    Hematol Oncol Clin North Am; 2015 Oct; 29(5):875-93. PubMed ID: 26461148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells.
    Lim KPH; Milne P; Poidinger M; Duan K; Lin H; McGovern N; Abhyankar H; Zinn D; Burke TM; Eckstein OS; Chakraborty R; Sengal A; Scull B; Newell E; Merad M; McClain KL; Man TK; Ginhoux F; Collin M; Allen CE
    Blood Adv; 2020 Jan; 4(1):87-99. PubMed ID: 31899802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
    Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
    Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ddPCR Analysis Reveals BRAF V600E Mutations Are Infrequent in Isolated Pituitary Langerhans Cell Histiocytosis Patients.
    Nellan A; Bodlak A; Mirsky DM; Mulcahy Levy J; Garrington TP; Foreman NK; Gilani A; Hayashi M
    J Neuropathol Exp Neurol; 2020 Dec; 79(12):1313-1319. PubMed ID: 32930721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease.
    Abla O
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):386-395. PubMed ID: 38066856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.
    Tóth B; Kiss N; Hársing J; Kárpáti S; Csomor J; Bödör C; Tímár J; Rásó E
    Virchows Arch; 2020 Nov; 477(5):749-753. PubMed ID: 32372223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
    Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
    Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Prevalence of
    Liu X; Zhang Y; Zhou CX
    Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
    Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
    Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.